Le Lézard
Classified in: Business
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DermTech, Inc. - DMTK


NEW YORK, Nov. 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether DermTech and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On August 8, 2022, after the market closed, DermTech announced its second quarter 2022 financial results and revealed that the Company expected "a lower average selling price (ASP) for [its] DMT," due to "Medicare billing code edits . . . as well as less favorable collection patterns from commercial payors."

On this news, the Company's stock price fell $2.87, or 34%, to close at $5.56 per share on August 9, 2022. 

Then, on November 3, 2022, after the market closed, DermTech announced its third quarter 2022 financial results, reporting that billable sample volume "sequential growth was flat due to headwinds caused by limited commercial payer coverage." The Company attributed the disappointing growth to "commercial payer collection challenges [have] affect[ed] estimating ASP [average selling price]." As a result, DermTech expected "at least $13 million in assay revenue for the fullyear 2022," which is "below [its] previous guidance range." 

On this news, the Company's stock price fell $1.34, or 44.7%, to close at $1.66 per share on November 4, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

SOURCE Pomerantz LLP


These press releases may also interest you

at 17:00
zkLink, the leading zero-knowledge(ZK) Layer 3 infrastructure provider, today announced the launch of zkLink Nova, the industry's first aggregated Layer 3 zkEVM rollup network, based on zkSync's ZK Stack and zkLink Nexus. zkLink Nova unifies...

at 15:07
The secondary market for luxury watches is worth $25 billion. Analysts say it will outstrip the primary market by 2032. However, the WatchCharts Overall Index is down almost 40% since its March 2022 peak.While losses may have slowed in recent months,...

at 15:00
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. between June 4, 2021 and October 12, 2023, both dates inclusive (the "Class Period"), of the important April 15, 2024 lead plaintiff deadline....

at 13:49
We, Prime Minister of Canada Justin Trudeau and President of the Council of Ministers of Italy Giorgia Meloni, met today in Toronto, Ontario, to reaffirm the profound friendship and the shared values that bind Canada and Italy and to discuss our...

at 12:01
Sure, Phil Zamloot's team can make you a great trade show booth at a really good price. But that's not what makes him and his company, Metro Exhibits, so successful....

at 12:00
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Inari Medical, Inc. resulting from allegations that Inari Medical may have issued materially misleading...



News published on and distributed by: